Health Care & Life Sciences » Biotechnology | Esperion Therapeutics Inc.

Esperion Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
70.60
160.00
236.00
252.00
258.00
265
Gross Income
70.60
160.00
236.00
252.00
258.00
265
SG&A Expense
22,688.10
36,064.00
49,804.00
75,898.00
168,724.00
204,320
EBIT
22,758.70
36,224.00
50,040.00
76,150.00
168,982.00
204,585
Unusual Expense
2,586.90
-
-
-
-
-
Non Operating Income/Expense
194.00
119.00
724.00
1,052.00
308.00
275
Interest Expense
936.60
270.00
520.00
376.00
198.00
100
Pretax Income
26,088.10
36,375.00
49,784.00
74,978.00
166,988.00
201,810
Consolidated Net Income
26,088.10
36,375.00
49,784.00
74,978.00
166,988.00
201,810
Net Income
26,088.10
36,375.00
49,784.00
74,978.00
166,988.00
201,810
Net Income After Extraordinaries
26,088.10
36,375.00
49,784.00
74,978.00
166,988.00
201,810
Net Income Available to Common
26,088.10
36,375.00
49,784.00
74,978.00
166,988.00
201,810
EPS (Basic)
3.31
2.22
2.26
3.33
6.98
7.54
Basic Shares Outstanding
7,885.90
16,374.10
22,019.80
22,544.50
23,933.30
26,754.30
EPS (Diluted)
3.31
2.22
2.26
3.33
6.98
7.54
Diluted Shares Outstanding
7,885.90
16,374.10
22,019.80
22,544.50
23,933.30
26,754.30
EBITDA
22,688.20
36,064.00
49,804.00
75,898.00
168,724.00
204,320
Non-Operating Interest Income
-
-
1,500.00
2,600.00
2,500.00
2,600

About Esperion Therapeutics

View Profile
Address
3891 Ranchero Drive
Ann Arbor Michigan 48108
United States
Employees -
Website http://www.esperion.com
Updated 07/08/2019
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.